Search

everythinglearnresearchcommunity

for

Search:↓

Mixing finasteride pills with stemoxydine is not recommended due to potential solubility and safety issues. It's advised to consult a healthcare provider for professionally formulated topical finasteride products.

Finasteride and minoxidil stopped hair loss and improved urinary issues for a 34-year-old user. Despite some sexual side effects, the user plans to continue finasteride, while considering restarting minoxidil.

The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.

The user left their 2.5 mg pills at home and is considering using 5% topical minoxidil as a substitute. They also inquire about where to obtain over-the-counter minoxidil pills.

A 28-year-old male with severe hair loss is considering switching from finasteride to dutasteride due to side effects from oral finasteride, despite using topical minoxidil and finasteride with minimal improvement. He seeks advice on whether dutasteride might be effective without affecting libido.

Switching from finasteride to dutasteride led to hairline regression and scalp issues for some users, prompting a return to finasteride. Users reported better maintenance and regrowth with finasteride compared to dutasteride, despite using oral minoxidil throughout.

PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.

Using dutasteride anally as a hair loss treatment, with humorous and satirical comments on its effects and implications.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

A user in the UAE is facing customs issues with ordering Fluridil (Eucapil) and is considering ordering smaller quantities or switching to Pyrilutamide. They are also using finasteride daily to maintain hair and are unsure of Fluridil's effectiveness.

A user underwent a second hair transplant for increased density and to address hair loss in the crown area, with 3,800 grafts at a cost of 2,200 euros at Estepalace, including additional services. Some commenters discussed the appearance of the hairline and the importance of using DHT blockers like finasteride or dutasteride post-transplant.

Switching from finasteride to dutasteride can cause initial shedding, but many see long-term hair regrowth and stabilization. Responses vary, with some experiencing fewer side effects and others finding it less effective.

The conversation discusses various hair loss treatments, including pyrilutamide, RU58841, topical dutasteride, oral minoxidil, and oral finasteride/dutasteride. It also mentions potential treatments like PP405, Verteporfin, GT20029, and AMP303.

The conversation is about using topical Dutasteride for hair loss. One tip given is to apply it to the scalp.

The conversation is about hair loss treatments, focusing on finasteride and considering a switch to dutasteride due to hairline recession. Users suggest trying minoxidil or dermarolling before switching, while others recommend dutasteride for more aggressive hair loss.

Topical finasteride reduces scalp DHT, with some going systemic. Using 0.025% at 1ml per day can stabilize hair loss without side effects.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

The user is considering adding a topical treatment to their current regimen of finasteride and oral minoxidil to protect their temple area, with options like piro, RU58841, or topical finasteride or dutasteride. They are advised against overcomplicating their treatment, but another user suggests a topical with 8% minoxidil/dutasteride for better results.

The user plans to stop using finasteride due to side effects but will continue using minoxidil. They are concerned about hair regrowth without finasteride.

The conversation discusses the use of Verteporfin in treating hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The user reduced serum DHT by 60% using Advanced Trichology's natural DHT blocker but saw no improvement in hair loss. They are considering switching to finasteride due to its proven effectiveness in inhibiting scalp DHT.

A 25-year-old male experienced hair loss after taking breaks from oral dutasteride and minoxidil, leading to concerns about losing progress. He is advised to remain consistent with his current regimen and avoid adding spironolactone.

A 29-year-old male with diffuse thinning plans to start minoxidil and finasteride soon but is concerned about potential shedding before a big event in late April/early May. He is considering whether to start treatment now or wait until after the event.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

A 20-year-old is considering switching from finasteride to dutasteride during a steroid cycle to better manage hair loss, then returning to finasteride afterward. They are concerned about the risks of post-finasteride syndrome from frequently changing medications.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

OP is considering adding dutasteride to their regimen of finasteride and minoxidil to address hair loss plateauing. Users suggest oral minoxidil, microneedling, and possibly a hair transplant, with mixed opinions on dutasteride's effectiveness for temple regrowth.